Related references
Note: Only part of the references are listed.Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis
Maxime Samson et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Trial of Tocilizumab in Giant-Cell Arteritis
J. H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis
Carol A. Langford et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy(vol 7, 43953, 2017)
F. David Carmona et al.
SCIENTIFIC REPORTS (2017)
Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis
Ester Planas-Rigol et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis
Marc Corbera-Bellalta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study
Cristian Labarca et al.
RHEUMATOLOGY (2016)
Giant Cell Arteritis
Gary S. Hoffman
ANNALS OF INTERNAL MEDICINE (2016)
Ustekinumab for the treatment of refractory giant cell arteritis
Richard Conway et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice
Xiaoqian Wang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Peter M. Villiger et al.
LANCET (2016)
Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling
Georgina Espigol-Frigole et al.
SCIENCE SIGNALING (2016)
Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling
Georgina Espigol-Frigole et al.
SCIENCE SIGNALING (2016)
Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family
Hideaki Hasegawa et al.
FRONTIERS IN IMMUNOLOGY (2016)
IL-12p40 Homodimer Ameliorates Experimental Autoimmune Arthritis
Seon-Yeong Lee et al.
JOURNAL OF IMMUNOLOGY (2015)
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Michele W. L. Teng et al.
NATURE MEDICINE (2015)
Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis
Marc Corbera-Bellalta et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Relapses in Patients With Giant Cell Arteritis Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
Marco A. Alba et al.
MEDICINE (2014)
Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis
Georgina Espigol-Frigole et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
J. C. Jennette et al.
ARTHRITIS AND RHEUMATISM (2013)
Autoimmune Memory T Helper 17 Cell Function and Expansion Are Dependent on Interleukin-23
Christopher J. Haines et al.
CELL REPORTS (2013)
Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis
Benjamin Terrier et al.
ARTHRITIS AND RHEUMATISM (2012)
Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis
Maxime Samson et al.
ARTHRITIS AND RHEUMATISM (2012)
Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study
Sudha Visvanathan et al.
RHEUMATOLOGY (2011)
Th17 and Th1 T-Cell Responses in Giant Cell Arteritis
Jiusheng Deng et al.
CIRCULATION (2010)
Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis
F. Brentano et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo
Mandy J. McGeachy et al.
NATURE IMMUNOLOGY (2009)
Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis:: A cross-sectional screening of fifty-four prospectively followed patients
Ana Garcia-Martinez et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis
E. Lozano et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Lauren W. Collison et al.
NATURE (2007)
Gelatinase expression and proteolytic activity in giant-cell arteritis
Marta Segarra et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Five clinical conundrums in the management of giant cell arteritis
Maria C. Cid et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2007)
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis - A randomized trial
Gary S. Hoffman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis
M. C. Cid et al.
RHEUMATOLOGY (2006)
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6
D Yen et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis
Y Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis
J Hernández-Rodríguez et al.
RHEUMATOLOGY (2004)
Anti-interleukin-12 antibody for active Crohn's disease
PJ Mannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
DJ Cua et al.
NATURE (2003)
Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis
WM Krupa et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
B Oppmann et al.
IMMUNITY (2000)
Share Paper
